Oversea-Chinese Banking Corp (OCBC)’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.01M Buy
83,573
+13,567
+19% +$355K 0.04% 198
2026
Q1
$1.97M Buy
+70,006
New +$1.86M 0.05% 181
2025
Q4
– Sell
-34,795
Closed -$827K – 371
2025
Q3
$827K Sell
34,795
-13,845
-28% -$342K 0.02% 224
2025
Q2
$1.18M Buy
48,640
+33,875
+229% +$790K 0.03% 200
2025
Q1
$374K Buy
14,765
+5,865
+66% +$153K 0.01% 311
2024
Q4
$236K Sell
8,900
-22,823
-72% -$619K 0.01% 338
2024
Q3
$919K Buy
31,723
+10,938
+53% +$319K 0.03% 244
2024
Q2
$570K Sell
20,785
-7,988
-28% -$220K 0.02% 272
2024
Q1
$799K Sell
28,773
-1,744
-6% -$48.4K 0.02% 245
2023
Q4
$879K Buy
30,517
+22,129
+264% +$669K 0.03% 199
2023
Q3
$269K Sell
8,388
-3,220
-28% -$114K 0.01% 333
2023
Q2
$419K Buy
11,608
+2,636
+29% +$103K 0.02% 238
2023
Q1
$366K Buy
8,972
+3,152
+54% +$136K 0.02% 251
2022
Q4
$298K Buy
+5,820
New +$279K 0.02% 288

Other funds holding PFE

Oversea-Chinese Banking Corp (OCBC)'s PFE Position: Q2 2026 in Review

Oversea-Chinese Banking Corp (OCBC) increased its Pfizer (PFE) stake by 19% in Q2 2026, buying an estimated $355K and bringing the position to 83,573 shares worth $2.01M. The position accounts for 0.04% of the portfolio, ranked #198.

Oversea-Chinese Banking Corp (OCBC) first reported a position in PFE in Q4 2022 and has held it in 14 quarters since. 2,841 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Oversea-Chinese Banking Corp (OCBC) held 83,573 shares of Pfizer worth $2.01M as of Q2 2026.
  • Oversea-Chinese Banking Corp (OCBC) bought 13,567 Pfizer shares in Q2 2026, an estimated $355K.
  • Pfizer made up 0.04% of Oversea-Chinese Banking Corp (OCBC)'s portfolio in Q2 2026, its #198 holding.
  • Oversea-Chinese Banking Corp (OCBC) first reported a position in Pfizer in Q4 2022 and has held it in 14 quarters since.
  • 2,841 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Oversea-Chinese Banking Corp (OCBC)'s 13F filing for Q2 2026, filed 11 Aug 2026.